No Evidence of an Increased Risk for Malignancy Associated with Natalizumab Therapy in 9 Years of Postmarketing Surveillance

Cynthia Carrillo-Infante, Sarah Gheuens, Made Wenten, Pei-Ran Ho, Irene Koulinska, Sandra Richman